caa a22 4500 477070000 CHVBK 20180405111422.0 cr unu---uuuuu 170330e19960901xx s 000 0 eng 10.1007/BF01691958 doi (NATIONALLICENCE)springer-10.1007/BF01691958 Azithromycin versus penicillin V in the treatment of paediatric patients with acute streptococcal pharyngitis/tonsillitis [Elektronische Daten] [B. O'Doherty, G. Pilfors, P. Quinn, A. Howard, F. Bradbury, M. Scully, O. Clarke, J. Kiernan, M. Ryan, P. O'Kelly, P. Williams, T. Khong, J. Hamill, A. Burman, C. Khatri, P. Agrawal, P. Soares, I. Hughes] The efficacy and safety of azithromycin and penicillin V in the treatment of acute streptococcal pharyngitis/tonsillitis in paediatric patients were compared in a double-blind, double-dummy prospective study. A total of 489 children (age range, 2-13 years) were randomized to receive treatment with penicillin V (125-250 mg 4 × daily for 10 days) or azithromycin in an oral suspension (10 or 20 mg/kg 1 × daily for 3 days). Only patients with baseline cultures positive forStreptococcus pyogenes and complete clinical and microbiological assessments at the end of therapy and follow-up one month later were included in the efficacy analysis. A satisfactory clinical response (cure or improvement) was recorded in 99% of the 10 mg/kg azithromycin group, 100% of the 20 mg/kg azithromycin group, and 97% of the penicillin V group at the end of therapy (day 12-14). At the follow-up evaluation (day 28-30), relapse rates in patients cured or improved at the end of therapy were 6%, 5%, and 2%, respectively. Bacteriological eradication rates at the end of therapy were 98% in both azithromycin groups and 92% in patients who received penicillin V (p=0.011); pathogen recurrence was recorded at follow-up in 4% of the 20 mg/kg azithromycin group and in 6% of both the 10 mg/kg azithromycin and penicillin V groups. Treatment-related adverse events, the majority of mild to moderate severity, occurred in 13% of patients in the 20 mg/kg azithromycin group, 9% in the 10 mg/kg azithromycin group, and 5% in the penicillin V group. Azithromycin in a dosage of 10 or 20 mg/kg/day once daily for three days was as safe and effective as penicillin V administered four times daily in the treatment of paediatric patients with acute pharyngitis/tonsillitis. MMV Medizin Verlag GmbH, 1996 O'Doherty B. Merrion Lodge, Gorey, County Wexford, Republic of Ireland aut Pilfors G. Vardcentralen, Sweden aut Quinn P. Sligo, Republic of Ireland aut Howard A. Sligo, Republic of Ireland aut Bradbury F. Kilkenny, Republic of Ireland aut Scully M. Navan, Republic of Ireland aut Clarke O. Navan, Republic of Ireland aut Kiernan J. Navan, Republic of Ireland aut Ryan M. Ballincollig, Republic of Ireland aut O'Kelly P. Carlow, Republic of Ireland aut Williams P. Leicester, UK aut Khong T. Leicester, UK aut Hamill J. Leicester, UK aut Burman A. Manchester, UK aut Khatri C. Manchester, UK aut Agrawal P. Bedford, UK aut Soares P. Ilford, UK aut Hughes I. Waterloo, UK aut European Journal of Clinical Microbiology and Infectious Diseases Springer-Verlag 15/9(1996-09-01), 718-724 0934-9723 15:9<718 1996 15 10096 https://doi.org/10.1007/BF01691958 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF01691958 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- O'Doherty B. Merrion Lodge, Gorey, County Wexford, Republic of Ireland aut NATIONALLICENCE 700 1- Pilfors G. Vardcentralen, Sweden aut NATIONALLICENCE 700 1- Quinn P. Sligo, Republic of Ireland aut NATIONALLICENCE 700 1- Howard A. Sligo, Republic of Ireland aut NATIONALLICENCE 700 1- Bradbury F. Kilkenny, Republic of Ireland aut NATIONALLICENCE 700 1- Scully M. Navan, Republic of Ireland aut NATIONALLICENCE 700 1- Clarke O. Navan, Republic of Ireland aut NATIONALLICENCE 700 1- Kiernan J. Navan, Republic of Ireland aut NATIONALLICENCE 700 1- Ryan M. Ballincollig, Republic of Ireland aut NATIONALLICENCE 700 1- O'Kelly P. Carlow, Republic of Ireland aut NATIONALLICENCE 700 1- Williams P. Leicester, UK aut NATIONALLICENCE 700 1- Khong T. Leicester, UK aut NATIONALLICENCE 700 1- Hamill J. Leicester, UK aut NATIONALLICENCE 700 1- Burman A. Manchester, UK aut NATIONALLICENCE 700 1- Khatri C. Manchester, UK aut NATIONALLICENCE 700 1- Agrawal P. Bedford, UK aut NATIONALLICENCE 700 1- Soares P. Ilford, UK aut NATIONALLICENCE 700 1- Hughes I. Waterloo, UK aut NATIONALLICENCE 773 0- European Journal of Clinical Microbiology and Infectious Diseases Springer-Verlag 15/9(1996-09-01), 718-724 0934-9723 15:9<718 1996 15 10096 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer